1. **Identification**

   **Product Identifier:** Atropine Sulfate Ophthalmic Solution USP, 1%
   **Synonyms:** Benzeneacetic acid, α-(hydroxymethyl)-, 8-methyl-8-azabicyclo-[3.2.1]oct-3-yl ester, endo-(±), sulfate

   **National Drug Code (NDC):**
   - 17478-215-02
   - 17478-215-05
   - 17478-215-15

   **Recommended Use:** Pharmaceutical.

   **Company:** Akorn, Inc.
   1925 West Field Court, Suite 300
   Lake Forest, Illinois 60045

   **Contact Telephone:** 1-800-932-5676

   **Email:** customer.service@akorn.com

   **Emergency Phone Number:** CHEMTREC 1-800-424-9300 (U.S. and Canada)

2. **Hazard(s) Identification**

   **Physical Hazards:** Not classifiable.

   **Health Hazards:** Not classifiable.

   **Symbol(s):** Not classifiable.

   **Signal Word:** None.

   **Hazard Statement(s):** None.

   **Precautionary Statement(s):** None.

   **Hazards Not Otherwise Classified:** Not classifiable.

   **Supplementary Information:** While this material is not classifiable as hazardous under the OSHA standard, this SDS contains valuable information critical to safe handling and proper use of the product. This SDS should be retained and available for employees and other users of this product.
3. Composition/Information on Ingredients

<table>
<thead>
<tr>
<th>Chemical Name</th>
<th>CAS Number</th>
<th>Synonyms</th>
<th>Chemical Formula</th>
<th>Molecular Weight</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benzeneacetic acid, α-(hydroxymethyl)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester, endo-(±)-, sulfate</td>
<td>5908-99-6</td>
<td>Atropine Sulfate; Atropisol; Atropt</td>
<td>(C17H23NO3)2 • H2SO4 • H2O</td>
<td>694.85</td>
<td>1.0</td>
</tr>
</tbody>
</table>

Inactive ingredients: Purified Water; Hypromellose (2910) (0.5%); Benzalkonium Chloride (0.01%); Dibasic Sodium Phosphate; Edetate Disodium; Monobasic Sodium Phosphate, Hydrochloric Acid and/or Sodium Hydroxide may be added to adjust pH.

4. First Aid Measures

Ingestion: If a person vomits place them in the recovery position so that vomit will not reenter the mouth and throat. Rinse mouth. Keep victim warm and quiet. Loosen tight clothing such as a collar, tie, belt or waistband. If swallowed, seek medical advice immediately and show the container or label. Treat symptomatically and supportively. Ensure that medical personnel are aware of the material(s) involved and take precautions to protect themselves. Effects of exposure (ingestion) to substance may be delayed.

Eye Contact: Remove from source of exposure. Move individual(s) to fresh air. Check for and remove any contact lenses. Flush with copious amounts of water for at least 20 minutes. Effects of exposure may be delayed. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary. Ensure that medical personnel are aware of the material(s) involved and are aware of precautions to protect to protect themselves.

Skin Contact: Remove from source of exposure. Remove and isolate contaminated clothing and shoes. Flush with copious amounts of water for at least 20 minutes. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary. Ensure that medical personnel are aware of the material(s) involved and are aware of precautions to protect to protect themselves.

Inhalation: Remove from source of exposure. Move individual(s) to fresh air. Give artificial respiration if individual(s) are not breathing and call emergency medical service. If signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary. Ensure that medical personnel are aware of the material(s) involved
SDS: Atropine Sulfate Ophthalmic Solution USP, 1%

and are aware of precautions to protect themselves.

**Protection of First-Aiders:**
Use personal protective equipment (see section 8).

**Signs and Symptoms:**

Eye: May cause irritation and hypersensitivity (anaphylactic) in some individuals. May cause temporary light sensitivity. Overdosage (systemic toxicity) is manifested by flushing and dryness of the skin (a rash may be present in children), blurred vision, a rapid and irregular pulse, fever, abdominal distension in infants, mental aberration (hallucinations) unusual drowsiness, tachycardia, hyperpyrexia, vasodilation, urinary retention, diminished gastric motility and decreased secretion in salivary and sweat glands, pharynx, bronchi, nasal passages and loss of neuromuscular coordination. Severe reactions are manifested by low blood pressure (hypotension) with progressive respiratory depression. Coma and death have been reported in the very young. The main symptoms are drowsiness leading to coma. Atropine poisoning is rarely fatal. Once the drug is withdrawn, the mechanism of overdosage is self-limiting.

Skin: May cause irritation and hypersensitivity in some individuals. Toxic systemic effects may be induced by skin contact.

Ingestion: May cause irritation, vomiting, diarrhea and hypersensitivity in some individuals. Ingestion of atropine sulfate may induce systemic toxicity effects.

Inhalation: May cause irritation and hypersensitivity in some individuals.

Chronic Effects: May cause irritation and hypersensitivity. Prolonged application may produce local irritation characterized by follicular conjunctivitis, vascular congestion, edema, exudate, and an eczematoid dermatitis. Severe reactions are manifested by hypotension with progressive respiratory depression. Coma and death have been reported in the very young.

Target Organs: Eyes, central nervous system, heart, respiratory and digestive tract.

**Medical Conditions Aggravated by Exposure:**
Hypersensitivity to any of the components of the product. Persons with a previous history of susceptibility to
belladonna alkaloids may produce systemic symptoms of atropine poisoning.

Notes to Physician: Atropine may be incapacitating at doses of 10 to 20 mg per person.

5. **Firefighting Measures**

**Suitable Extinguishing Media:** Use extinguishing media for type of surrounding fire.

**Unsuitable Extinguishing Media:** Not determined.

**Specific Hazards Arising from the Chemical:**

**Hazardous Combustion Products:** These products include carbon oxides, nitrogen oxides, and sulfur oxides.

**Other Specific Hazards:** Closed containers may explode from the heat of fire.

**Special Protective Equipment Precautions for Firefighters:** Wear self-contained breathing apparatus and full and protective gear.

6. **Accidental Release Measures**

**Personal Precautions:** Keep unnecessary personnel away. Do not touch damaged containers or spilled material unless wearing appropriate personal protective equipment and clothing.

**Personal Protective Equipment:** For personal protection see section 8.

**Methods for Cleaning Up:** Dike ahead of liquid spills for later disposal. Absorb with inert material. Recover product and place in an appropriate container for disposal in accordance with local, state and federal regulations.

**Environmental Precautions:** Contain material and prevent release to basements, confined spaces, waterways or soil.

**Reference to Other Sections:** Refer to Sections 8, 12 and 13 for further information.

7. **Handling and Storage**

**Precautions for Safe Handling:** Handle in accordance with product label and/or product insert information. Handle in accordance with good industrial hygiene and safety practices.

**Conditions for Safe Storage, Including Any Incompatibilities:** Store according to label and/or product insert information. Store away from oxidizers.

**Specific End Use:** Pharmaceuticals.
8. Exposure Controls/Personal Protection

Occupational Exposure Guidelines:

<table>
<thead>
<tr>
<th>Common or Chemical Name</th>
<th>Employee Exposure Limits</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atropine Sulfate</td>
<td>OEL*: 2.5 µg/m³, 8 Hour TWA; OEL*: 4 µg/m³, 8 Hour TWA</td>
</tr>
</tbody>
</table>

* Occupational Exposure Levels (OELs) have been established by private industry.

Engineering Controls: Airborne exposure should be controlled primarily by engineering controls such as general dilution ventilation, local exhaust ventilation, or process enclosure. Local exhaust ventilation is generally preferred to general exhaust because it can control the contaminant at its source, preventing dispersion into the work area. An industrial hygiene survey involving air monitoring may be used to determine the effectiveness of engineering controls. Effectiveness of engineering controls intended for use with highly potent materials should be assessed by use of nontoxic surrogate materials.

Respiratory Protection: Where respirators are deemed necessary to reduce or control occupational exposures, use NIOSH-approved respiratory protection and have an effective respirator program in place (applicable U.S. regulation OSHA 29 CFR 1910.134).

Eyes: Safety glasses with side shields are recommended. Face shields or goggles may be required if splash potential exists or if corrosive materials are present. Approved eye protection (e.g., bearing the ANSI Z87 or CSA stamp) is preferred. Maintain eyewash facilities in the work area.

Hand: Chemically compatible gloves. For handling solutions, ensure that the glove material is protective against the solvent being used. Use handling practices that minimize direct hand contact. Employees who are sensitive to natural rubber (latex) should use nitrile or other synthetic non-latex gloves. Use of powdered latex gloves should be avoided due to the risk of latex allergy.

Skin: Protective laboratory coat, apron, or disposable garment.

9. Physical and Chemical Properties

<table>
<thead>
<tr>
<th>Physical State/Color:</th>
<th>Semi-solid/Colorless to light yellowish translucent.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Odor:</td>
<td>No data available.</td>
</tr>
<tr>
<td>Odor Threshold:</td>
<td>No data available.</td>
</tr>
<tr>
<td>pH:</td>
<td>No data available.</td>
</tr>
<tr>
<td>Melting Point:</td>
<td>No data available.</td>
</tr>
<tr>
<td>Freezing Point:</td>
<td>No data available.</td>
</tr>
<tr>
<td>Boiling Point:</td>
<td>No data available.</td>
</tr>
<tr>
<td>Flash Point:</td>
<td>No data available.</td>
</tr>
<tr>
<td>Evaporation Rate:</td>
<td>No data available.</td>
</tr>
<tr>
<td>Flammability (solid, gas):</td>
<td>No data available.</td>
</tr>
</tbody>
</table>
SDS: Atropine Sulfate Ophthalmic Solution USP, 1%

Flammability Limit - Lower: No data available.
Flammability Limit - Upper: No data available.
Vapor Pressure: No data available.
Vapor Density: No data available.
Relative Density: No data available.
Solubility(ies): Miscible in water.
Partition Coefficient (n-octanol/water): No data available.
Auto-Ignition Temperature: No data available.
Decomposition Temperature: No data available.
Viscosity: No data available.

10. Stability and Reactivity

Reactivity: No data available.
Chemical Stability: Stable under recommended storage conditions.
Possibility of Hazardous Reactions: No data available.
Conditions to Avoid (e.g., static discharge, shock, or vibration): No data available.
Incompatible Materials: No data available.
Hazardous Decomposition Products: No data available.

11. Toxicological Information

Information on the Likely Routes of Exposure:
Inhalation: May be harmful if inhaled. May cause respiratory tract irritation.
Ingestion: May be harmful if swallowed.
Skin Contact: May be harmful if absorbed through the skin. May cause skin irritation.
Eye Contact: May cause eye irritation.

Symptoms Related to the Physical, Chemical and Toxicological Characteristics: See Section 4. To the best of our knowledge, the chemical, physical and toxicological properties have not been thoroughly investigated.

Delayed and Immediate Effects of Exposure: No data available.

Acute Toxicity – Oral: LD<sub>50</sub>, Mouse: 468 mg/kg (Atropine Sulfate)
LD<sub>50</sub>, Rat: 500 mg/kg (Atropine Sulfate)

Acute Toxicity – Dermal: No data available.
Acute Toxicity – Inhalation: No data available.
Corrosivity: No data available.
Dermal Irritation: No data available.
Eye Irritation: No data available.
Sensitization: No data available.
Toxicokinetics/Metabolism: No data available.
Target Organ Effects: No data available.
Reproductive Effects: No data available.

Carcinogenicity:
National Toxicology Program (NTP): Not considered to be a carcinogen.
International Agency for Research on Cancer (IARC): Not considered to be a carcinogen.
SDS: Atropine Sulfate Ophthalmic Solution USP, 1%

Occupational Safety and Health Administration (OSHA): Not considered to be a carcinogen.

Mutagenicity: No data available.
Aspiration Hazard: No data available.

12. **Ecological Information**

Ecotoxicity
Aquatic: EC\textsubscript{50}, Daphnia magna: 356 mg/l, 24 hours (Atropine Sulfate).
Terrestrial: No data available.

Persistence and Degradability: No data available.
Bioaccumulative Potential: No data available.
Mobility in Soil: No data available.
Other Adverse Effects:

13. **Disposal Considerations**

Dispose of all waste in accordance with Federal, State and local regulations.

14. **Transport Information**

UN Number: Not applicable.
UN Proper Shipping Name: Not applicable.
Transport Hazard Class(es): Not applicable.
Packing Group: Not applicable.
DOT: Not regulated as a hazardous material.

International Air Transport Association (IATA): Not regulated as a dangerous good.

International Maritime Dangerous Good (IMDG): Not regulated as a dangerous good.

15. **Regulatory Information**

US Federal Regulations:
TSCA Inventory
This product is a drug regulated by the Food and Drug Administration (FDA), and is not regulated by TSCA.
CERCLA Hazardous Substance and Reportable Quantity: Not listed.
SARA 313: Not listed.
SARA 302: Not listed.

State Regulations
Massachusetts: Not listed.
New Jersey: Not listed.
Pennsylvania: Not listed.
California Proposition 65: Not listed.
SDS: Atropine Sulfate Ophthalmic Solution USP, 1%

16. Other Information

Not made with natural rubber latex.

<table>
<thead>
<tr>
<th>NFPA Rating: (Atropine Sulfate)</th>
<th>HMIS Classification: (Atropine Sulfate)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Health: 4</td>
<td>Health: 3</td>
</tr>
<tr>
<td>Flammability: 0</td>
<td>Flammability: 0</td>
</tr>
<tr>
<td>Reactivity: 0</td>
<td>Physical Hazard: 0</td>
</tr>
</tbody>
</table>

Revision Date: 07/21/2014

Revision Number: 0

Disclaimer: This document is generated to distribute health, safety and environmental data. It is not a specification sheet and none of the displayed data should be construed as a specification. Information on this MSDS sheet was obtained from sources which we believe are reliable, and we believe that the information is complete and accurate. However, the information is provided without any warranty, express or implied, regarding its correctness. Some of the information presented and conclusions drawn are from sources other than direct test data of the substance. The conditions or methods of handling, storage, use and disposal of the product are beyond our control and may also be beyond our knowledge. It is the user’s responsibility to determine the suitability of any material for a specific purpose and to adopt such safety precautions as may be necessary. If the product is used as a component in another product, this MSDS information may not be applicable. For these reasons, we do not assume any responsibility and expressly disclaim liability for any loss, damage or expense arising out of or in any way connected with the handling, storage, use or disposal of this product.